Exercise and GLP-1 RA on Insulin Secretion (EXISECRET)
Status
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to determine the effect of endurance exercise on insulin secretory capacity, alone or in addition to treatment with the glucagon-like-peptide receptor agonist semaglutide, in patients with type 2 diabetes.
Full description
The effects of endurance exercise alone or in addition to treatment with glucagon-like- peptide receptor agonists on insulin secretory capacity, will be determined in patients with type 2 diabetes.
Included patients will be randomized to either 12 weeks of endurance exercise training 3 times a week or therapeutical treatment with semaglutide for 3 months followed by 12 weeks of endurance exercise training 3 times a week. Insulin secretory capacity will be determined by hyperglycemic clamp method before and after.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Diagnosed with type 2 diabetes
- BMI 28-35
- Moderately preserved insulin secretory capacity (determined by glucagon test)
Exclusion criteria
- Insulin treatment
- Hypertension grade 3
- Heart disease
- Medical history with pancreatitis
- Diagnosed with neuropathy
- Excessive alcohol consumption
- Any condition that would interfere with the protocol.
Trial design
Primary purpose
Allocation
Interventional model
Masking
30 participants in 3 patient groups
Trial contacts and locations
Loading...
Central trial contact
Arthur Ingersen, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal